Selected drugs that received regulatory approval in 2012. Source: BCIQ: BioCentury Online Intelligence

Company

Product

Indication

2012 approval

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)

Juxtapid lomitapide

Homozygous familial hypercholesterolemia (hoFH)

U.S.

Affymax Inc. (NASDAQ:AFFY)/ Takeda Pharmaceutical Co. Ltd. (Tokyo:4502)

Omontys peginesatide

Anemia in chronic kidney disease (CKD) patients who are on dialysis

U.S.

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA)

Adasuve Staccato loxapine

Schizophrenia or bipolar disorder

U.S.

Alimera Sciences Inc(NASDAQ:ALIM)/ pSivida Corp. (NASDAQ:PSDV; ASX:PVA)

Iluvien fluocinolone acetonide

Chronic diabetic macular edema (DME)

Austria/ Portugal/U.K.

Almirall S.A(Madrid:ALM)/Forest Laboratories Inc. (NYSE:FRX)/Menarini Group/Quintiles Transnational Corp.

Tudorza Pressai aclidinium bromide (Bretaris/Eklira Genuair - EU)

Chronic obstructive pulmonary disease (COPD)

EU/U.S.

Amarin Corp. plc (NASDAQ:AMRN)

Vascepa icosapent ethyl

Severe hypertriglyceridemia

U.S.

Amylin Pharmaceuticals LLC/Bristol-Myers Squibb Co. (NYSE:BMY)/Alkermes plc(NASDAQ:ALKS)

Bydureon exenatide once weekly using Alkermes' drug delivery technology

Type II diabetes

U.S.

Arena Pharmaceuticals Inc. (NASDAQ:ARNA)/ Eisai Co. Ltd. (Tokyo:4523; Osaka:4523)

Belviq lorcaserin

Chronic weight management

U.S.

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

Iclusig ponatinib

Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)

U.S.